Division of Nephrology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, Taiwan.
Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Nanomedicine (Lond). 2017 Nov;12(22):2741-2756. doi: 10.2217/nnm-2017-0256. Epub 2017 Sep 8.
We used resveratrol (Res)-loaded nanoparticles (Res NPs) as a novel method for improving the pharmacokinetic properties of Res and analyzed the effect of Res NPs in chronic kidney disease (CKD).
MATERIALS & METHODS: We coupled anti-kidney injury molecule-1 antibodies to Res NPs and analyzed safety and efficacy.
Res NPs had low toxicity and induced autophagy. Res NPs inhibited the NLRP3 inflammasome and IL-1β secretion. Higher NLRP3 expression levels were observed in peripheral blood monocytic cells of CKD patients than healthy individuals. Treatment with kidney injury molecule-1-Res NPs significantly reduced creatinine and protected against tubulointerstitial injury in a murine model of CKD.
Res NPs through NLRP3 inflammasome attenuation and autophagy induction may be as a strategy to prevent CKD.
我们使用白藜芦醇（Res）负载的纳米颗粒（Res NPs）作为一种提高 Res 药代动力学特性的新方法，并分析 Res NPs 在慢性肾病（CKD）中的作用。
我们将抗肾损伤分子-1 抗体与 Res NPs 偶联，并分析其安全性和疗效。
Res NPs 毒性低，能诱导自噬。Res NPs 抑制 NLRP3 炎性小体和 IL-1β 的分泌。与健康个体相比，CKD 患者外周血单核细胞中 NLRP3 的表达水平更高。用肾损伤分子-1-Res NPs 治疗可显著降低肌酐水平，并可防止 CKD 小鼠模型的肾小管间质损伤。
Res NPs 通过 NLRP3 炎性小体的衰减和自噬的诱导，可能是预防 CKD 的一种策略。
